Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Public health policy and health economics

2287 - The European Cancer Patient Coalition’s White Policy Paper on the Value of Innovation in Oncology


09 Sep 2017


Public health policy and health economics


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP


Lydia Makaroff


Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385


L. Makaroff1, F. De Lorenzo2, K. Apostolidis1, J. Pelouchova3, A. Winterbottom1, S. Chrostowski4, D. Cimpoeru1, N. Bolanos Fernandez5, A. Rek1, I. Manneh-Vangramberen1, L. Baker6, F. Florindi1

Author affiliations

  • 2 ,, F.A.V.O. - Federazione Italiana delle Associazioni di Volontariato in Oncologia, 00187 - Roma/IT
  • 3 ,, General Faculty Hospital, VFN Charles University, 128 08 - Prague/CZ
  • 4 ,, Let's Win Health Foundation, 00-547 - Warsaw/PL
  • 5 ,, GEPAC, Madrid/ES
  • 6 Public Affairs, Interel, 1000 - Brussels/BE


Abstract 2287


Each year, over 3 million Europeans are diagnosed with cancer, and over 1 million Europeans die from the disease. With a growing and ageing population, action is urgently needed to address this major global health and societal concern. Action is needed to help policy-makers understand how they can improve access to innovative cancer care and treatment. Aim: To produce a policy white paper that summarised the major recommendations to improve access to innovative cancer care and treatment for Europeans diagnosed with cancer.


The European Cancer Patient Coalition developed the white paper over a one-year period, in collaboration with Interel Public Affairs, oncology experts, and the patient organisations that form the membership of the European Cancer Patient Coalition.


The “Value of Innovation in Oncology” white paper presented the position of the European Cancer Patient Coalition on innovation in oncology, and offered recommendations to help reduce variations in access to innovation and to involve patients in decision-making. It summarised the European Cancer Patient Coalition’s stance on topics related to innovation in oncology, with the overarching goal to shrink international variations in the time to patients’ access to innovation in oncology, while, at the same time, it considered the sustainability of health systems and how to ensure innovation is celebrated and accessed appropriately. Finally, the paper focused on recommendations to increase the involvement of patients in key aspects of innovation, including assessment and access.


More work is needed at the European and national level to improve the access of Europeans with cancer to innovative treatment and care and to ensure that people with cancer are actively involved in decisions throughout the care pathway.

Clinical trial identification

Legal entity responsible for the study

European Cancer Patient Coalition


Bristol-Myers Squibb, Eli Lilly and Company, MSD, Novartis, Pfizer, and Roche.


L. Makaroff, A. Rek, I. Manneh-Vangramberen, F. Florindi: Employee of the European Cancer Patient Coalition F. De Lorenzo: President of the European Cancer Patient Coalition K. Apostolidis: Vice President of the European Cancer Patient Coalition J. Pelouchova: Secretary of the European Cancer Patient Coalition A. Winterbottom: Treasurer of the European Cancer Patient Coalition S. Chrostowski, D. Cimpoeru, N. Bolanos Fernandez: Board member of the European Cancer Patient Coalition L. Baker: Employee of Interel Public Affairs Belgium. Clients of Interel Public Affairs include some pharmaceutical companies. The European Cancer Patient Coalition has received support from Merck, Pfizer, Roche, MSD, Bristol-Myers Squibb, AbbVie, Amgen, AstraZeneca, Baxter, BI, Celgene, Helsinn, Ipsen, Lilly, & Novartis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.